Biointron Weekly Reports
News?
Huge thanks to all who came to Biointron’s Annual Year-End Networking Party last week! We were excited to see so many familiar and new faces to share an evening filled with inspiring knowledge, conversations, and laughter. ?? To everyone who joined us, thank you for making this celebration so special, and we’re excited to continue growing together in the new year.
Last week, Biointron exhibited at the 3rd Annual Meeting of the Antibody Society of Japan and the Chinese Antibody Society's 2024 mAbTalk Symposium! Our expert team is happy to answer any follow-up questions at [email protected] or +1 (732) 790-8340.?
In our latest episode of the new Antibody ABCs video series, we define hybridoma technology. Watch the playlist here.
This Week’s News
Trends – Shifting Focus for Infectious Diseases
The FDA has revoked Emergency Use Authorizations (EUAs) for multiple COVID-19 monoclonal antibody (mAb) therapies, including those developed by Eli Lilly, AstraZeneca, Vir Biotechnology, and Regeneron. This decision reflects the challenges of targeting rapidly mutating viruses like SARS-CoV-2, which have rendered the mostly expired drugs no longer effective against circulating SARS-CoV-2 strains. As circulating variants became resistant to these specific mAbs, the industry now faces an urgent need to develop next-generation solutions that are broader, more durable, and resilient to viral evolution.
The high mutation rate of SARS-CoV-2 has highlighted a significant vulnerability in variant-specific mAb therapies. This situation underscores the importance of identifying broadly neutralizing antibodies or targeting conserved viral epitopes that are less prone to mutation. Such strategies will not only address current viral challenges but also provide a foundation for future-proof therapies against evolving pathogens.
Meanwhile, scientists at the Icahn School of Medicine at Mount Sinai have developed the AMETA Nanobody Platform, an approach designed to combat rapidly mutating viruses like SARS-CoV-2. AMETA uses engineered nanobodies attached to a human IgM scaffold to target multiple stable regions of the virus simultaneously, significantly enhancing binding strength and reducing the risk of resistance. Lab tests and preclinical studies in mice show AMETA’s effectiveness against SARS-CoV-2 variants, including Omicron, and even the related SARS-CoV virus. The platform’s ability to disrupt viral structures and clump particles together sets it apart from traditional antibodies. Researchers highlight its potential to address other fast-mutating pathogens, such as HIV and influenza, offering a flexible, durable, and cost-effective solution for managing current and future infectious diseases.
Scientists from the 新西兰奥克兰大学 have linked the post-COVID surge of respiratory illnesses like RSV and Strep A to waning antibody levels caused by pandemic restrictions. A study of 150 blood donors over three years showed that while antibodies against SARS-CoV-2 increased due to vaccination and infection, immunity to pathogens like Group A Streptococcus and RSV declined. This drop resulted from reduced exposure to germs during lockdowns, mask-wearing, and travel bans, which limited their circulation. Once restrictions eased, these pathogens rebounded at higher levels, impacting more vulnerable populations. These results highlight the need for awareness and preparedness for future immunity gaps.?
领英推荐
Upcoming Events
To close the end of the year, our final event is being held this week at the Antibody Engineering & Therapeutics US. The event is being held at the Marriott Marquis San Diego, San Diego, CA. Meet us at Booth #109!
Promotions – 40% OFF Abinvivo Products! ??
Explore Abinvivo, our brand for ???????????????????? ?????? ???? ???????? ????????????????! ?? Save on your project with our ????????-?????????????? ???????????????? - 40% off sitewide! Now with online checkout and 1 week delivery:
RushMab - Gene? is your go-to solution for quick plasmid production, designed specifically for antibody-related research. We offer a 4-day turnaround, delivering high-quality, transfection-grade expression plasmids for IgG, Fab, VHH, and ScFv sequences. We provide quantities of 100 μg (sufficient for 100 ml culture) with scalability up to grams. Using the reliable pcDNA3.4 backbone, we also accommodate custom vectors. Each plasmid undergoes Sanger sequencing verification and endotoxin control, ensuring precision and safety.
?
New Products & Reports?
Learn more about Biointron at www.biointron.com, or contact us at [email protected] and +1 (732) 790-8340